miR-20 regulated genes and pathways as targets for therapeutic intervention

Details for Australian Patent Application No. 2007333106 (hide)

Owner Asuragen, Inc.

Inventors Brown, David; Byrom, Mike; Johnson, Charles D.; Bader, Andreas G.

Agent Pizzeys

Pub. Number AU-A-2007333106

PCT Pub. Number WO2008/073919

Priority 60/869,295 08.12.06 US; 60/915,026 30.04.07 US

Filing date 10 December 2007

Wipo publication date 19 June 2008

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

9 July 2009 PCT application entered the National Phase

  PCT publication WO2008/073919 Priority application(s): WO2008/073919

17 November 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007333107-miR-21 regulated genes and pathways as targets for therapeutic intervention

2007333105-Non-standard amino acid conjugates of amphetamine and processes for making and using the same